2023版ESMO临床实践指南:早期乳腺癌的诊断、治疗与随访(上篇) 在2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practic...
PusztaiL,ReganMM,SparanoJ,SpanicT,SwainS,TjulandinS,ToiM,TrapaniD,TuttA,XuB,CuriglianoG,HarbeckN;ESMOGuidelinesCommittee.Earlybreastcancer:ESMOClinicalPracticeGuidelinefordiagnosis,treatmentandfollow-upt.AnnOncol.2023 Dec8:S0923-7534(23)05104-9.doi:10.1016/j.annonc.2023.11.016. 下载文档 收藏 分享...
Proffered Paper session:Breast cancer, early stage Educational session:Optimising overall survival in advanced renal cancer Educational session:Therapeutic view on tumour immune microenvironment: It's TIME Educational session:First-line therapy in ...
[4]Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 Oct;32(10):1216-1235. [5]Early Breast Cancer Trialist...
Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220 F Cardoso,S Kyriakides,S Ohno,... - 《Annals of Oncology Official Journal of the European Society for Medical Oncology》 被引量: 0发表: 2021年...
107P Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer. ABSTRACT BOOK of the ESMO Breast Cancer, 107P. 2023; 8(1S4):9. 3. FDA expands early breast cancer ...
DESTINY-Breast03研究的脑转移亚组分析表明,T-DXd组和T-DM1组的ORR分别为63.9%和33.4%;CR率分别为27.8%和2.8%;中位PFS分别为15个月和3个月[5]。2023年ESMO大会中公布的DESTINY-Breast01、02和03研究脑转移探索性汇总分析结果表明,对于稳定性脑转移患者,T-DXd组颅内ORR为45.2%,中位CNS PFS为12.3个月;对于...
2. National Cancer Institute, SEER. Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed October 18, 2023. 3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on rec...
O'Shaughnessy J, Rastogi P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan;24(1):...
To explore the current clinical management of early-stage breast cancer (BC) patients, identify areas of controversy, and interrogate how treating physicians implement latest advances.We conducted a 27-item survey, disseminated in two stages: paper distribution at selected BC sessions at the ESMO 201...